Skip to main content
SpringerLink
Log in

CTLA-4 et Toll-like récepteurs: de nouvelles cibles en immunothérapie

  • Chapter
Les thérapies ciblées

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 381 Accesses

Abstrait

Plusieurs données cliniques suggèrent que la modulation des réponses immunitaires peut être une stratégie anti-tumorale efficace. Ládministration de BCG est reconnue comme un traitement efficace des cancers superficiels de la vessie. Par analogie avec les vaccinations contre certains pathogènes intracellulaires, des protocoles de vaccination ont utilisé le BCG comme adjuvant et permis ľobtention de résultats cliniques intéressants. Ľallogreffe de cellules hématopoïétiques a montré de longue date sa capacité à éradiquer des maladies leucémiques réfractaires aux traitements conventionnels. Récemment, ľintroduction des anticorps monoclonaux dans ľarsenal thérapeutique de ľoncologie médicale et de ľhématologie a étayé ľimportance du système immunitaire anti-tumoral. Ces résultats ont motivé un plus ample développement des bithérapies favorisant les réponses immunitaires anti-tumorales. Ainsi, nous aborderons ici les données fondamentales et cliniques concernant ľutilisation de ligands agonistes des récepteurs de la famille TOLL et des anticorps neutralisant la molécule CTLA-4.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Stephen CL, Gough SCL, Walker L.S.K, Sansom DM (2005) CTLA4 gene polymorphism and autoimmunity. Immunol Rev 204: 102–15

    Article  Google Scholar 

  2. Lemaitre B (2004) The road to Toll. Nat Rev Immunol 4: 521–7

    Article  PubMed  CAS  Google Scholar 

  3. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991–1045

    PubMed  CAS  Google Scholar 

  4. Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13: 114–9

    Article  PubMed  CAS  Google Scholar 

  5. Srivastava PK (2005) Immunotherapy for human cancer using heat shock proteinpeptide complexes. Curr Oncol Rep 7: 104–8

    Article  PubMed  CAS  Google Scholar 

  6. Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516–21

    Article  PubMed  CAS  Google Scholar 

  7. Killeen SD, Wang JH, Andrews EJ et al. (2006) Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer 95: 247–52

    Article  PubMed  CAS  Google Scholar 

  8. van Duin D, Medzhitov R, Shaw AC (2006) Triggering TLR signaling in vaccination. Trends Immunol 27: 49–55

    Article  PubMed  Google Scholar 

  9. Huang B, Zhao J, Li H, et al. (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65: 5009–14

    Article  PubMed  CAS  Google Scholar 

  10. Miggin SM, O’Neill LA (2006) New insights into the regulation of TLR signaling. J Leukoc Biol 80: 220–6

    Article  PubMed  CAS  Google Scholar 

  11. Parker LC, Prince LR, Sabroe I (2007) Translational Mini-Review Series on Toll-like Receptors: Networks regulated by Toll-like receptors mediate innate and adaptive immunity. Clin Exp Immunol 147: 199–207

    PubMed  CAS  Google Scholar 

  12. Sutmuller RP, Morgan ME, Netea MG, et al. (2006) Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol 27: 387–93

    Article  PubMed  CAS  Google Scholar 

  13. Hopkins PA, Sriskandan S (2005) Mammalian Toll-like receptors: to immunity and beyond. Clin Exp Immunol 140: 395–407

    Article  PubMed  CAS  Google Scholar 

  14. Schmausser B, Andrulis M, Endrich S, et al. (2005) Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 295: 179–85

    Article  PubMed  CAS  Google Scholar 

  15. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987–95.

    Article  PubMed  CAS  Google Scholar 

  16. Kawai T, Akira S (2006) TLR signaling. Cell Death Differ 13: 816–25

    Article  PubMed  CAS  Google Scholar 

  17. Seki E, Tsutsui H, Nakano H, et al. (2001) Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol 166: 2651–7

    PubMed  CAS  Google Scholar 

  18. Tsan MF (2006) Toll-like receptors, inflammation and cancer. Semin Cancer Biol 16: 32–7

    Article  PubMed  CAS  Google Scholar 

  19. Perabo FG, Muller SC (2004) Current and new strategies in immunotherapy for superficial bladder cancer. Urology 64: 409–21

    Article  PubMed  Google Scholar 

  20. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471–84

    Article  PubMed  CAS  Google Scholar 

  21. Miyazaki J, Kawai K, Oikawa T, et al. (2006) Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guerin through Toll-like receptor signalling. BJU Int 97: 860–4

    Article  PubMed  CAS  Google Scholar 

  22. Kelly MG, Alvero AB, Chen R, et al. (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66: 3859–68

    Article  PubMed  CAS  Google Scholar 

  23. Klaffenbach D, Rascher W, Rollinghoff M, et al. (2005) Regulation and signal transduction of toll-like receptors in human chorioncarcinoma cell lines. Am J Reprod Immunol 53: 77–84

    Article  PubMed  CAS  Google Scholar 

  24. Hassan F, Islam S, Tumurkhuu G, et al. (2006) Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer 6: 281

    Article  PubMed  Google Scholar 

  25. Molteni M, Marabella D, Orlandi C, Rossetti C (2006) Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Letter 235: 75–83

    Article  CAS  Google Scholar 

  26. Li K, Chen Z, Kato N, et al. (2005) Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 280: 16739–47

    Article  PubMed  CAS  Google Scholar 

  27. Lang KS, Georgiev P, Recher M, et al. (2006) Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest 116: 2456–63

    Article  PubMed  CAS  Google Scholar 

  28. Salaun B, Coste I, Rissoan MC, et al. (2006) TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176: 4894–901

    PubMed  CAS  Google Scholar 

  29. Liew FY, Xu D, Brint EK, O’Neill LA (2005) Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 5: 446–58

    Article  PubMed  CAS  Google Scholar 

  30. Stockfleth E, Trefzer U, Garcia-Bartels C, et al. (2003) The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149 Suppl 66: 53–6

    Article  PubMed  CAS  Google Scholar 

  31. Schulze HJ, Cribier B, Requena L, et al. (2005) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 152: 939–947

    Article  PubMed  CAS  Google Scholar 

  32. Speiser DE, Lienard D, Rufer N, et al. (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115: 739–46

    PubMed  CAS  Google Scholar 

  33. Friedberg JW, Kim H, McCauley M, et al. (2005) Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105: 489–95

    Article  PubMed  CAS  Google Scholar 

  34. Pashenkov M, Goess G, Wagner C, et al. (2006) Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24: 5716–24

    Article  PubMed  CAS  Google Scholar 

  35. Carpentier A, Laigle-Donadey F, Zohar S, et al. (2006) Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncol 8: 60–6

    Article  PubMed  CAS  Google Scholar 

  36. Byrd-Leifer CA, Block EF, Takeda K, et al. (2001) The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 31: 2448–57

    Article  PubMed  CAS  Google Scholar 

  37. June CH, Bluestone JA, Nadler LM, Thompson CDB (1994) The B7 and CD28 receptor families. Immunol Today 7: 321–31

    Article  Google Scholar 

  38. Egen JG, Allison JP (2002) Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16: 23–35

    Article  PubMed  CAS  Google Scholar 

  39. Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233–58

    Article  PubMed  CAS  Google Scholar 

  40. Shiratori T, Miyatake S, Ohno H, et al. (1997) Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 5: 583–9

    Article  Google Scholar 

  41. Linsley PS, Bradshaw J, Greene J, et al. (1996) Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 6: 535–43

    Article  Google Scholar 

  42. Rudd CE, Schneider H (2003) Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 3: 544–6

    Article  PubMed  CAS  Google Scholar 

  43. Lin H, Rathmell JC, Gray GS, Thompson CB, et al. (1998) Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Blockade Accelerates the Acute Rejection of Cardiac Allografts in CD28-deficient Mice: CTLA4 Can Function Independently of CD28. J Exp Med 188: 199–204

    Article  PubMed  CAS  Google Scholar 

  44. Masteller EL, Chuang E, Mullen AC, et al. (2000) Structural Analysis of CTLA-4 Function In Vivo. J Immunol 164: 5319–27

    PubMed  CAS  Google Scholar 

  45. Marengere LE, Waterhouse P, Duncan GS, et al. (1996) Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 272: 1170–3

    Article  PubMed  CAS  Google Scholar 

  46. Schneider H, Prasad KV, Shoelson SE, Rudd CE (1995) CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp Med 181: 351–5

    Article  PubMed  CAS  Google Scholar 

  47. Chuang E, Fisher TS, Morgan RW, et al. (2000) The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 13: 313–22

    Article  PubMed  CAS  Google Scholar 

  48. Guntermann C, Alexander DR (2002) CTLA-4 suppresses proximal TCR signaling in resting human CD4+ T cells by inhibiting ZAP-70 Tyr319 phosphorylation: a potential role for tyrosine phosphatases. J Immunol 168: 4420–29

    PubMed  CAS  Google Scholar 

  49. Calvo CR, Amsen D, Kruisbeek AM (1997) Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor σ and ZAP70. J Exp Med 186: 1645–53

    Article  PubMed  CAS  Google Scholar 

  50. Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183: 2533–40

    Article  PubMed  CAS  Google Scholar 

  51. Cazzolli R, Carpenter L, Biden TJ, Schmitz-Peiffer C (2001) A role for protein phosphatase 2A-like activity, but not atypical protein kinase Cζ, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 50: 2210–18

    Article  PubMed  CAS  Google Scholar 

  52. Resjo S, Goransson O, Harndahl L, et al. (2002) Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes. Cell Signal 14: 231–38

    Article  PubMed  CAS  Google Scholar 

  53. Baroja ML, Vijayakrishnan L, Bettelli E, et al. (2002) Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. J Immunol 168: 5070–78

    PubMed  CAS  Google Scholar 

  54. Chikuma S, Imboden JB, Bluestone JA (2003) Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med 1: 129–35

    Google Scholar 

  55. Martin M, Schneider H, Azouz A, Rudd CE (2001) Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J Exp Med 11: 1675–81

    Article  Google Scholar 

  56. Fraser JH, Rincon M, McCoy KD, Le Gros G (1999) CTLA4 ligation attenuates AP-1, NFAT and NF-κB activity in activated T cells. Eur J Immunol 29: 838–44

    Article  PubMed  CAS  Google Scholar 

  57. Olsson C, Riesbeck K, Dohlsten M, Michaelsson E (1999) CTLA-4 ligation suppresses CD28-induced NF-κB and AP-1 activity in mouse T cell blasts. J Biol Chem 274: 14400–5

    Article  PubMed  CAS  Google Scholar 

  58. Brunner MC, Chambers CA, Chan FK, et al. (1999) CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 162: 5813–5820

    PubMed  CAS  Google Scholar 

  59. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 10: 762–74

    Article  Google Scholar 

  60. Woo EY, Yeh H, Chu CS, et al. (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 9: 4272–6

    Google Scholar 

  61. Fallarino F, Grohmann U, Hwang KW, et al. (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4: 1206–12

    Article  PubMed  CAS  Google Scholar 

  62. Walunas TL, Lenschow DJ, Bakker CY, et al. (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 5: 405–413

    Article  Google Scholar 

  63. Tivol EA, Borriello F, Schweitzer AN, et al. (1994) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 5: 541–547

    Google Scholar 

  64. Luhder F, Hoglund P, Allison JP (1998) Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 3: 427–32

    Article  Google Scholar 

  65. Croxford JL, O’Neill JK, Ali RR, et al. (1998) Local gene therapy with CTLA-4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. Eur J Immunol 28: 3904–3916

    Article  PubMed  CAS  Google Scholar 

  66. Ueda H, Howson JM, Esposito L (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506–11

    Article  PubMed  CAS  Google Scholar 

  67. Kwon E.D, Foster B.A, Hurwitz A.A, et al. (1999) Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade imunotherapy. Proc Natl Acad Sci USA 96: 15074–79

    Article  PubMed  CAS  Google Scholar 

  68. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734–6

    Article  PubMed  CAS  Google Scholar 

  69. Yang YF, Zou JP, Mu J, et al. (1997) Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 57: 4036–41

    PubMed  CAS  Google Scholar 

  70. Kwon ED, Hurwitz AA, Foster BA, et al. (1997) Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 94: 8099–103

    Article  PubMed  CAS  Google Scholar 

  71. Shrikant P, Khoruts A, Mescher MF (1999) CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell-and IL-2-dependent mechanism. Immunity 11: 483–93

    Article  PubMed  CAS  Google Scholar 

  72. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355–66

    Article  PubMed  Google Scholar 

  73. Phan GQ, Yang JC, Sherry RM, et al. (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372–7

    Article  PubMed  CAS  Google Scholar 

  74. Sanderson K, Scotland R, Lee P, et al. (2005) Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 4: 741–50

    Article  Google Scholar 

  75. Beck KE, Blansfield JA, Tran KQ, et al. (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24: 2283–9

    Article  PubMed  CAS  Google Scholar 

  76. Ribas A, Camacho LH, Lopez-Berestein G, et al. (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23: 8968–77

    Article  PubMed  CAS  Google Scholar 

  77. Maker AV, Phan GQ, Attia P, et al. (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12: 1005–16

    Article  PubMed  Google Scholar 

  78. Maker AV, Attia P, Rosenberg SA, et al. (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175: 7746–54

    PubMed  CAS  Google Scholar 

  79. Reuben JM, Lee BN, Li C, et al. (2006) Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106: 2437–44

    Article  PubMed  CAS  Google Scholar 

  80. Lute KD, May KF Jr, Lu PHuman, et al. (2005) CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 106: 3127–33

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM U645 EFS Bourgogne Franche Comté, Université de Franche Comté, 3, boulevard Alexandre-Fleming, 25000, Besançon

    R. Bedel, C. Borg & P. Saas

  2. Service ďoncologie médicale, CHU Jean Minjoz, 3, boulevard Alexandre-Fleming, 25000, Besançon

    R. Bedel, C. Borg & P. Saas

Authors
  1. R. Bedel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Borg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Saas
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France

About this chapter

Cite this chapter

Bedel, R., Borg, C., Saas, P. (2008). CTLA-4 et Toll-like récepteurs: de nouvelles cibles en immunothérapie. In: Les thérapies ciblées. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-36008-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-36008-4_12

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-36007-7

  • Online ISBN: 978-2-287-36008-4

Publish with us

Policies and ethics

Search

Navigation